Pain Therapeutics – Industry Gathers to Assess Animal Models and Market Access

LONDON - May 7, 2014 - PRLog -- The truly global event features attendees from all over the world including Australia, Belgium, France, Germany, Netherlands, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom and USA

Due to high demand, availability to attend the 14th annual instalment is now strictly limited. For those who are interested places can be booked online at www.pain-therapeutics.com (http://www.smi-online.co.uk/goto/2014pain-therapeutics.asp?emref=P-104EL210000023&amp)

EVENT HIGHLIGHTS INCLUDE:

GW Pharmaceuticals talk Cannabinoids: "The role of cannabinoids as a useful therapeutic modality in various chronic pain states has been subject to discussion and investigation over the last decade in particular. The recent success of Sativex, where several cannabinoids are combined with other plant components has cast new light on mechanisms of action and optimal disease targets. The past present and future of cannabinoids as analgesics are discussed in this presentation.” Stephen Wright, R&D Director

Spotlight session on “Advances in Opioids” will feature three key pharma presentations. Following on from this, attendees will be invited to participate in a panel debate on strategies to reduce opioid abuse which will be led by Mundipharma, Nektar and Morpheus.

Joint keynote presentation by Spinifex Pharmaceuticals and Imperial College London with a focus on EMA401 Phase 2 clinical findings: Spinifex CEO, Tom McCarthy and Praveen Anand, Professor of Clinical Neurology, Lead Clinician for Pain Services from Imperial College, London provide an exclusive update

Receive key insights from Janssen Pharmaceutical on Fulranumab clinical development: Medical Leader, Dr Kelly will be presenting attendees with Phase 2 efficacy and safety data for Fulranumab and will also be discussing nerve growth factors with a focus on antibody inhibitors, injury and inflammation.

OGB Consulting Discuss Animal Models: Independent Consultant Professor Odd-Geir Berge will be making a case study driven presentation entitled "The Translation Gap and Assessing Failures, Case Study1 – Pre-Clinical Perspective." Discuss the translation from animal models to man, failed pain mechanisms and experimental models versus clinical trials.

This is just a snippet of what will be covered. Other speakers will include UCB, University of Oxford, AbbVie, Eli Lilly, Neuroscience Technologies plus many more. Click here (http://www.smi-online.co.uk/goto/2014pain-therapeutics.as...) to see the full speaker line up, short interviews and conference agenda.

PAIN THERAPEUTICS
19th - 20th May 2014
NEW VENUE: Holiday Inn Kensington Forum, London UK
www.pain-therapeautics.com (http://www.smi-online.co.uk/goto/2014pain-therapeutics.asp?emref=P-104EL210000023&amp)

The 14th annual conference is sponsored by Bertin Pharma, Centre for Human Drug Research and PRA International.

To book contact John Collins at jcollins@smi-online.co.uk

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.

More information can be found at www.smi-online.co.uk